Background: Cardiac cachexia, loss of muscle mass associated with congestive heart failure (CHF), is associated with increased morbidity and shorter survival times in people, but an association between cardiac cachexia and survival has not been reported in dogs.
cardiac cachexia and cause reduced food intake, decreased muscle protein synthesis, and increased protein catabolism. 2 In humans, cachexia is linked to poor wound healing, lower exercise capacity, reduced strength, impaired immune function, and perceived poor quality of life. 1, 2 Many of these findings are also present in dogs with cardiac cachexia. 1 Cachexia in human CHF patients is an independent risk factor for poor prognosis and shorter survival times. 3, 4 Cachexia's effect on survival might be compounded in companion animals as some of the signs associated with cachexia are important factors in decisions about euthanasia. 5 However, the role of cardiac cachexia in survival of dogs with CHF has not been reported.
Approximately 10% of human CHF patients have cardiac cachexia although, depending on the definition and the patient population, prevalence rates can be up to 42%. 2, 4, 6 Despite many years of debate, there is still no single definition for cachexia in humans, which contributes to the variable prevalence. Proposed diagnostic criteria for human cachexia include weight loss of at least 5% in 12 months or less in combination with at least 3 of 5 signs: decreased muscle strength, fatigue, anorexia, low fat-free mass index, or abnormal serum biochemistry (ie, increased inflammatory markers, anemia, or low serum albumin). 7 Despite this published consensus, other definitions have been used for research studies. One of the most common is the loss of at least 5% of body weight over 12 months or less. 4, 8, 9 Definitions relying on weight loss as a criterion for the definition of cachexia, with or without additional criteria, however, is problematic in that body weight is an insensitive measure of muscle loss which can delay the diagnosis of cachexia until the disease is more advanced. This is particularly an issue in CHF where there can be fluid accumulation that can mask weight loss. In humans, loss of lean body mass and, more specifically, muscle mass occurs before substantial body weight is lost. 10 Therefore, measuring lean body mass or muscle mass might be preferable for the diagnosis of cachexia. 11 Loss of muscle can be quantified by advanced imaging modalities such as computed tomography or dual-energy x-ray absorptiometry, which require anesthesia or heavy sedation in companion animals, or by ultrasound. [11] [12] [13] However, clinically, the easiest approach is to evaluate muscle condition score (MCS). 14 Comparing prevalence of cachexia based on weight loss versus muscle loss has not been reported in dogs.
Therefore, the objectives of this study were to determine the prevalence of cachexia in dogs with CHF using definitions of weight loss or muscle loss and to compare clinical and laboratory variables, as well as survival times between dogs with and without cardiac cachexia.
| METHODS
Electronic medical records were searched to identify dogs diagnosed with CHF caused by degenerative mitral valve disease (DMVD) or dilated cardiomyopathy (DCM) by the Cummings Veterinary Medical Center's Cardiology Service between January 2015 and May 2018. This date range was selected because the hospital's current electronic medical record system was launched in 2015, and MCS has been recorded for all animals evaluated in cardiology appointments since that time. All dogs were assessed by echocardiography (Vivid E9 GE Medical Systems, Milwaukee, Wisconsin). The diagnosis of DMVD was based on signalment, a left apical systolic murmur, typical changes to the mitral valve leaflets on echocardiography, and the presence of mitral regurgitation on color-flow Doppler. To be included in this study, dogs with DMVD had to have at least a grade 3/6 systolic murmur and evidence of left atrial dilatation, defined as a left atrial-toaortic root ratio of at least 1.6 on 2-dimensional (2D) echocardiography.
A diagnosis of DCM was based on the presence of left atrial enlargement, left ventricular dilatation, and a fractional shortening ≤25% on a 2D and M-mode echocardiography. Dogs were classified as having CHF based on a combination of clinical signs and echocardiography, along with either radiographic evidence of cardiogenic pulmonary edema or presence of ascites or pleural effusion judged to be cardiogenic in origin. Echocardiography was performed using standard techniques 15 by a board-certified veterinary cardiologist or a supervised cardiology resident.
Exclusion criteria included dogs that were diagnosed with CHF at <1 year of age, dogs with CHF caused by other cardiac diseases, and dogs with other major concurrent diseases that could affect survival (eg, cancer, preexisting chronic kidney disease). Information on other diseases was determined from review of the medical records.
Medical records were retrospectively reviewed using a standardized data form to collect the following data from the visit at which CHF was diagnosed: signalment, body weight, heart rate, arrhythmias, murmur grade, echocardiographic measurements, CBC and serum biochemistry results, underlying disease, ACVIM stage, concurrent diseases, body condition score (BCS, on a 1-9 scale), and MCS (normal, mild, moderate, or severe muscle loss). 14 were considered underweight and those >5/9 were considered overweight. In addition to data from the date of diagnosis of CHF, body weights 6 and 12 months before diagnosis and 3, 6, 9, and 12 months after diagnosis were also collected when available. If ascites was noted, body weights after abdominocentesis were preferentially collected. If abdominocentesis was not performed, the presence of ascites was noted. The date and cause of death, if not still alive, were also recorded. If survival information was not available in the medical record, the primary care veterinarian was contacted or, if any information was still unavailable, the owner was contacted. If the owner could not be contacted, the dog was considered lost to follow-up. 
| Data analysis

| RESULTS
Of the 269 dogs that met the inclusion criteria, 218 dogs had DMVD and 51 dogs had DCM. Median age at diagnosis of CHF was 11.0 years (range, 1.8-17.1 years) with 54% male dogs and 46% female dogs ( Table 1) Cachexia was defined as dogs with mild, moderate, or severe muscle loss based on the muscle condition score. 14 T A B L E 2 Serum biochemistry and hematologic values of 269 dogs with congestive heart failure. Cachexia was defined as dogs with mild, moderate, or severe muscle loss based on the muscle condition score. 14 7%] in the current study did not have muscle loss).
Therefore, it is critical to measure both BCS and MCS, along with body weight, in all dogs.
In addition to low BCS being associated with a shorter survival time, dogs that were overweight or obese (BCS >5/9) also had a shorter survival time compared to those with a BCS = 4-5/9 at the time of diagnosis of CHF. This is in contrast to many human studies that have found an "obesity paradox," in which people with heart failure that are overweight or even obese have longer survival times. 17, 18 The difference in survival could not be detected based on BCS in dogs with CHF, although dogs that lost weight had shorter survival times than those that maintained or gained weight. 16 Similarly, a difference in survival could not be detected based on BCS in cats with CHF, but cats with the lowest or the highest body weights had shorter survival times. 19 The inability of these previous studies to detect a difference in BCS could be related to differences in underlying diseases between humans, dogs, and cats or could be because of the small sample size (the dog 16 and cat 19 16 One possible explanation for the shorter survival time in the current study is that the obesity paradox now appears to be related more to extra lean body mass in most overweight human patients than to obesity per se. 20 However, if excess weight is not associated with more lean body mass but is actually associated with cachexia, the beneficial effects are lost.
In fact, concurrent obesity and muscle loss in people ("sarcopenic obesity") might be associated with even shorter survival times than obesity or muscle loss alone. 21 In the current study, 30. 003 on multivariable analysis) and dogs with a BCS > 5/9 (P = .03 on univariate analysis and P = .003 on multivariable analysis) had shorter survival times point and thus avoids the pitfalls of relying on past records that often have large gaps in weight histories. Finally, even if accurate body weight data were available, it appears to be less sensitive for identifying cachexia than muscle loss in humans and likely in dogs. Of human patients with cancer that did not meet the inclusion criterion for cachexia of ≥5% weight loss, 41% had ≥5% muscle loss over the same period, suggesting that muscle loss is a more sensitive measure of cachexia. 10 In addition to MCS and BCS, results of the current study also showed that dogs with important arrhythmias had a shorter survival time compared with dogs without these arrhythmias, as was seen in previous studies. 22, 23 Azotemia was also an independent predictor of survival time. Azotemia has also been identified as a risk factor in studies of people with heart failure. 24 In addition, serum creatinine concentrations are higher in dogs with increasing severity of heart disease, 25 with 23% of dogs with advanced heart failure in 1 study having azotemia. 26 However, azotemia results must be interpreted with caution in the current study since laboratory testing was performed at variable time points with relation to the diagnosis of CHF (ie, it was measured on the hospital visit when CHF was first diagnosed, but some were before and others were after diuretic administration). In dogs with CHF, azotemia might be secondary to cardiac medications, as all dogs with known preexisting renal disease were excluded.
In addition to comparing survival times, clinical and laboratory variables were compared between dogs with and without cardiac cachexia.
Dogs with cachexia were significantly older, more likely to have DCM, and had lower BCS, blood pressure, hematocrit, hemoglobin, and albumin concentrations and higher chloride concentrations. Lower albumin and hemoglobin concentrations occur in people with cardiac cachexia reflecting malnutrition. 27, 28 The findings of lower blood pressure, higher chloride, or the greater likelihood of having DCM have not been previously reported in people or dogs with cardiac cachexia and require further study. It is also important to be aware that muscle loss also occurs in older dogs even in the absence of disease, where it is called sarcopenia. Because CHF occurs more commonly in older dogs, cachexia and sarcopenia can occur concurrently so it is difficult to discern whether muscle loss in these dogs was caused by cardiac cachexia, sarcopenia, or a combination of the two. It also is possible that the weight and muscle loss identified at the time of diagnosis of CHF was because of other undiagnosed diseases.
There are a number of limitations to the current study which are important to consider. This was a retrospective case study, so not all desired information was available in the medical records nor was it collected at the same time points in all dogs, even if it was collected during the hospitalization for the first diagnosis of CHF (eg, body weight and laboratory results). Another limitation is that MCS was not assessed by the same individual and studies in dogs 29 and cats 30 have shown some inter-and intraobserver variability.
However, in our hospital's cardiology service, MCS is reviewed and confirmed on every animal by the attending cardiologist or the cardiology resident, so there are a limited number of clinicians assigning these scores.
The high prevalence of cachexia and the association between cardiac cachexia and survival in dogs as well as in people with CHF suggests that muscle loss is important to evaluate in dogs with heart disease. Although few specific treatments are currently available, there is active research on treatments for cachexia in dogs and humans. 31, 32 However, it will be important to identify cachexia as early as possible when nutritional or drug treatments are more likely to be successful. The results of this study suggest that MCS is a clinically relevant method to detect cachexia in dogs with CHF at a single time point. This supports the recommendations to measure body weight, BCS, and MCS on every dog at every visit. 14, 33 
